• Funding will support recruitment, commercial partnerships, and further development of Semarion’s SemaCyte cell assaying platform, which turns adherent cells into liquid reagents to enable novel drug screening methodologies
• Investors include Parkwalk Advisors, University of Cambridge Seed Funds, Martlet Capital, and angel investors
News
We are excited to announce the launch of our new course, providing the training and examination required to become a IRCA Accredited GMP Pharmaceutical Quality System Lead Auditor.
Following on from the successful PR330 IRCA QMS Pharmaceutical Suppliers ISO9001/PQG Lead Auditor course, RSSL is launching the new GMP Pharmaceutical Quality Systems (GMP/ICHQ10) Lead Auditor Course from Spring 2022!
BioIVT will showcase its complete range of products and services for cell and gene therapy and immuno-oncology drug developers
Nottingham-based contract research organisation (CRO) Cellomatics Biosciences has made a key business development appointment in support of its ambitious growth plans.
OXFORD, UK February 21, 2022 – PrecisionLife Limited, a global techbio company driving precision medicine in chronic diseases with drug discovery, clinical development, and healthcare solutions based on its unique insights into disease biology, announces the appointment of Colin Stubberfield, Ph.D. as SVP Drug Discovery. He will be based at the Company’s UK headquarters in Oxfordshire, UK.
Air Products is proud to announce that it has been awarded Medical Device Regulation (MDR) EC Mark certificate for Medical Device liquid nitrogen for the UK.
14 February 2022
Leading pharmaceutical and biotech product development consultancy Boyds has further strengthened its clinical expertise with the appointment of Pharmaceutical Physician, Dr Harriet Gray Stephens to its Clinical and Medical Affairs group.
A decade ago, EY created a metric, the Firepower Index, to understand how life sciences companies were most likely to use M&A to drive portfolio growth. I am pleased to share with you that our 2022 edition is now available. The report was launched on 10 January, during our virtual EY Firepower panels in conjunction with the annual JP Morgan Healthcare Conference.
Nottingham based contract research organisation (CRO) Cellomatics Biosciences has expanded its team with the appointment of senior molecular biologist, Dr Lara De Tomasi, in response to recent growth and the continued increase in demand for its bespoke preclinical and early discovery phase expertise.